Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) announced that the US Patent and Trademark Office has allowed a patent application which covers a device that can apply heat and antimicrobial treatment through a detachable applicator surface comprising copper or silver to provide heat conductivity and a source of antimicrobial agent.
The patent applies to both Therma Bright's InterceptCS Cold Sore Prevention Device and TherOZap Insect Bite Relief Device.
Specific to the InterceptCS device, the heat and antimicrobial treatment technology is combined as the solution for the prevention of cold sores, the company said. As for the TherOZap device, the treatment technology aims to reduce the inflammatory response, relieving the symptoms of pain, itch and inflammation associated with insect bites and stings.
READ: Therma Bright closes C$6M private placement with institutional investors
"This is exciting news for Therma Bright and our TherOZap Insect Relief Device and InterceptCS Cold Sore Prevention Device," said Rob Fia, CEO of Therma Bright in a statement. "This allowed U.S. patent application further protects our valued intellectual property (IP) as we continue to transform innovation into wellness."
The company has previously announced that it has engaged a top virology research laboratory in Canada to study the TherOZap technology's ability to inactivate live Zika virus in culture media and that the TherOZap, which utilizes specialized materials, coatings and heat, was able to limit Zika virus (ZIKV) replication in cell cultures.
Therma Bright is currently carrying out design upgrades to both devices and expects to complete prototyping during Q2. In addition, the company plans to continue its research with the new TherOZap design on Zika and other mosquito-borne diseases during 2022.
Therma Bright is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges.
Contact Ritika at ritika@proactiveinvestors.com